 The article discusses the impact of meningococcal group BOMV vaccines, such as VAMeng.BC registered trademark symbol, in inducing moderate protection against near-seria gonorrhoea and their effectiveness in heterologous contexts, particularly in individuals older than 40 years old. However, the article also highlights that the effectiveness of VAMeng.BC registered trademark symbol in younger children has usually been higher than 60% with results markedly higher when evaluated based on mortality rates, and there is strong evidence that VAMeng.BC registered trademark symbol may induce cross-protection against heterologous and meningitis strains and engonorrhoea. This article was authored by Rolando Filipeo Chorazzi.